Abbott Laboratories vs. Seres Therapeutics, Inc.
Abbott Laboratories (ABT) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| ABT | MCRB | |
|---|---|---|
| Market Cap | $178.19 billion | $53.04 million |
| Revenue (TTM) | $46.59 billion | $1.88 million |
| Net Income (TTM) | $5.42 billion | $-22,463,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | MCRB | |
|---|---|---|
| P/E Ratio | 33.56 | — |
| Price / Book | 3.44 | 1.54 |
| Price / Sales | 3.83 | 28.17 |
ABT and MCRB split the valuation factors evenly.
Profitability
| ABT | MCRB | |
|---|---|---|
| Net Margin | 11.65% | -1192.94% |
| Return on Equity | 10.48% | -65.05% |
ABT leads on 2 of 2 profitability factors.
Dividend
| ABT | MCRB | |
|---|---|---|
| Dividend Yield | 2.43% | — |
| Payout Ratio | 81.55 | — |
ABT and MCRB split the dividend factors evenly.
Risk & Sentiment
| ABT | MCRB | |
|---|---|---|
| Short Interest | 0.57% | 47.82% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, MCRB overview, MCRB financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.